☆ 4.6 Article

Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications

PLOS ONE (2023)

Related references

Note: Only part of the references are listed.

Article Pathology

Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)

Emma J. de Ruiter et al.

Summary: This study compared the performance of two PD-L1 standardized assays and one laboratory-developed test in head and neck squamous cell carcinoma, revealing moderate concordance between different staining assays and considerable differences in PD-L1 positivity when using clinically relevant cutoffs. These findings suggest caution is needed when using PD-L1 expression to guide clinical practice.

MODERN PATHOLOGY (2021)

Add to Collection

Article Cell Biology

A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer

Aurelia Noske et al.

Summary: In this multicentre study, PD-L1-IC-positivity for SP142, 22C3 and 28-8 was found to be reproducible and analytically concordant in TNBC, suggesting analytical interchangeability. However, SP263 showed significantly higher PD-L1-IC-positivity, warranting further investigation into its relevance. Inter-reader agreement was moderate-to-strong for each assay, while inter-assay agreement varied from poor to strong.

HISTOPATHOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker

Kenneth Emancipator

Summary: The clinical development of pembrolizumab showed that PD-L1 expression level is a biomarker for patient response and cancer outcome, lowering the threshold for PD-L1 positivity expanded the patient population, and immune cell PD-L1 expression plays an important role in predicting tumor response in patients treated with pembrolizumab.

AAPS JOURNAL (2021)

Add to Collection

Article Pathology

Does Reproducibility Drive Clinical Accuracy?: Immunohistochemical Tests as Examples

Kenneth Emancipator

Summary: The study developed a model showing that analytical error tests meeting certain criteria can achieve clinical accuracy, even if reproducibility is less than 85%. This suggests that imperfect assays can still improve medical decision-making.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2021)

Add to Collection

Review Pathology

Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy

Emina Torlakovic et al.

MODERN PATHOLOGY (2020)

Add to Collection

Article Pathology

Interchangeability of PD-L1 laboratory-developed test by 22C3 antibody concentrate among ihc platforms in gastric cancer

Jimin Kim et al.

PATHOLOGY (2020)

Add to Collection

Article Medical Laboratory Technology

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

Karina Kulangara et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)

Add to Collection

Article Immunology

Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis

Xin Rui et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2019)

Add to Collection

Article Immunology

Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma

Aruna Nambirajan et al.

INDIAN JOURNAL OF MEDICAL RESEARCH (2019)

Add to Collection

Article Oncology

Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer

J. Adam et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients

Marius Ilie et al.

CANCER CYTOPATHOLOGY (2018)

Add to Collection

Article Oncology

Mechanisms of Resistance to PD-1 and PD-L1 Blockade

Theodore S. Nowicki et al.

CANCER JOURNAL (2018)

Add to Collection

Article Oncology

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

Shona Hendry et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

Add to Collection

Article Oncology

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Robert L. Ferris et al.

ORAL ONCOLOGY (2018)

Add to Collection

Article Genetics & Heredity

An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1

John Cogswell et al.

MOLECULAR DIAGNOSIS & THERAPY (2017)

Add to Collection

Article Oncology

A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform

Tzahi Neuman et al.

JOURNAL OF THORACIC ONCOLOGY (2016)

Add to Collection

Review Oncology

The blockade of immune checkpoints in cancer immunotherapy

Drew M. Pardoll

NATURE REVIEWS CANCER (2012)

Add to Collection

Article Multidisciplinary Sciences

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Y Iwai et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.